Author

R. Batteson

Observed names: R Batteson, Rachael Batteson, Rachael L. Batteson

Observed institution: BresMed

OpenAlex ID: A5114015167

Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy

2018 · Karl Patterson, Vimalanand Prabhu, et al. · European Urology Oncology · 29

PDF

Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping

2023 · Mo Yang, Helene Vioix, et al. · Value in Health · 12

Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection

2019 · Rachael Batteson, Rose Hart, et al. · PharmacoEconomics - Open · 5

PDF

Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK

2024 · Rachael Batteson, Emma Hook, et al. · Targeted Oncology · 3

PDF

Pcn226 the Cost-effectiveness and Relapse-reduction Benefit of Introducing Adjuvant Nivolumab for Patients With Completely With Resected Melanoma With Lymph Node Involvement or Metastatic Disease in the Uk

2019 · D. Ntais, R. Batteson, et al. · Value in Health · 3

HTA301 How End of Life Translates to Severity Weighting Under the New National Institute for Health and Care Excellence (NICE) Methodology. A Review of Past Oncology Appraisals

2023 · R. Batteson, S. Critchlow, et al. · Value in Health · 2

CO94 Tepotinib Compared With Chemoimmunotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC): Matching Adjusted Indirect Comparison (MAIC) of VISION in MET Exon 14 (METex14) Skipping NSCLC and KEYNOTE-189 in Wild-type NSCLC

2022 · H Vioix, A Hatswell, et al. · Value in Health · 2

Prm23 - Modelling Cancer Treatments in the Adjuvant Setting: a Targeted Literature Review (tlr) of Technology Appraisals (ta) of Adjuvant Therapies Submitted to the National Institute for Health and Care Excellence (nice) and a Case Study in Adjuvant Melanoma.

2018 · R Batteson, M Hemstock, et al. · Value in Health · 2

RWD51 Demonstrating Internal and External Validity in Real-World Datasets: A Case Study in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC)

2022 · R Batteson, E Hook, et al. · Value in Health · 1

CO23 Validating the Results of a Matching Adjusted Indirect Comparison (MAIC) in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC)

2022 · A Hatswell, R Batteson, et al. · Value in Health · 1

Prm21 - Modelling Survival of Patients With Completely Resected Advanced Melanoma With Adjuvant Treatment of Nivolumab Versus Observation

2018 · R Batteson, M Hemstock, et al. · Value in Health · 1

PDF

Comparative effectiveness in MET ex14 NSCLC: Outcomes from a propensity score–based analysis of 8 pooled real-world datasets (the TOGETHER study).

2026 · Laurent Greillier, Florian Guisier, et al. · Journal of Clinical Oncology

PDF

Indirect comparison of the effectiveness of tepotinib and immunotherapy in NSCLC with METex14 skipping alterations: Final propensity-scored analysis of eight pooled real-world datasets (TOGETHER) vs the VISION trial.

2026 · Florian Guisier, Laurent Greillier, et al. · Journal of Clinical Oncology

PDF

HTA143 Examining the Relationship Between the NICE WTP Threshold and the Severity Modifier

2025 · Simone Critchlow, Cameron Lilley, et al. · Value in Health

EE629 Quantifying the Impact of Inconsistencies in Economic Modeling Assumptions: A Case Study in Metastatic Colorectal Cancer

2025 · Rachael Batteson, Jaesh Naik, et al. · Value in Health

HTA6 A Decade in Decision Making: Reviewing Trends in STAS by NICE in Different Disease Areas

2025 · Rachael Batteson, Simone Critchlow · Value in Health

EE48 Cost-Effectiveness of Tepotinib Versus Docetaxel Monotherapy for Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Harboring METex14 Skipping in Finland

2024 · E Karttunen, S Jääskeläinen, et al. · Value in Health

HTA234 How Long Is the Weight? A Framework for Linear Interpolation of the National Institute for Health and Care Excellence (NICE) Severity Weighting in the Context of Probabilistic Sensitivity Analysis (PSA): A Case Study

2023 · S. Critchlow, T. Douglas, et al. · Value in Health

PDF

EE372 Modeling the Cost-Effectiveness in a Sub-Population: Tepotinib Versus Chemoimmunotherapy (C+IO) in Untreated Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METEX14) Skipping

2023 · R. Batteson, H. Vioix, et al. · Value in Health

PDF

CO168 A Propensity Score-Based Comparison of Tepotinib Versus Immunotherapy with/without Chemotherapy, Using Real-World Data in Previously Untreated Met Exon 14 (METEX14) Skipping Non-Small Cell Lung Cancer (NSCLC)

2023 · E. Hook, R. Batteson, et al. · Value in Health

PDF

EE146 Cost-effectiveness of Tepotinib for Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Harboring Metex14 Skipping Alterations in Spain

2023 · E. Arriola, R. Batteson, et al. · Value in Health

PDF

EE447 Budget Impact Analysis of Tepotinib in England for Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) Harboring MET Exon 14 (METex14) Skipping

2022 · T McLean, S Alexopoulos, et al. · Value in Health

PDF

PCR153 A Comparison of Utility Values Generated Using Different Methods From the Phase II Vision Trial of Tepotinib for Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METex14) Skipping

2022 · E Hook, H Vioix, et al. · Value in Health

Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in the United States.

2019 · Yichen Zhong, Yizhen Lai, et al. · Journal of Clinical Oncology

Validation of cost-effectiveness of trifluridine/tipiracil versus best supportive care and regorafenib for previously treated metastatic colorectal cancer in the UK using phase IIIb PRECONNECT early access clinical trial data in the real world setting.

2019 · Javier Sabater, Lewis Ralph, et al. · Journal of Clinical Oncology

Works count: 26

Citation count: 61

H-index: 3

I10-index: 2